Robert E. Richard - Jan 31, 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role: SVP, Technical Operations
Signature: /s/ Jason Cavalier, Attorney-in-Fact for Robert E. Richard, Ph.D.
Stock symbol: LYRA
Transactions as of: Jan 31, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/2/2023, 04:41 PM
Previous filing: Feb 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYRA	Common Stock	Award	$0	+30K		$0.00	30K	Jan 31, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYRA	Stock Option	Award	$0	+45K		$0.00	45K	Jan 31, 2023	Common Stock	45K	$2.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four (4) equal annual installments on the first four anniversaries of the grant date such that the RSUs will fully vest on January 31, 2027.
F2	This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.